Mod GRF 1-29 vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | SS-31 (Elamipretide) |
|---|---|---|
| Dose Range | 100 mcg–200 mcg | 20 mg–40 mg |
| Frequency | 3x daily | 1x daily |
| Cycle Length | 8–12 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |
What They Have in Common
Mod GRF 1-29, SS-31 (Elamipretide) are both commonly used for:
Key Differences
Unique to Mod GRF 1-29:
Unique to SS-31 (Elamipretide):
Which Has Stronger Evidence?
| Goal | Mod GRF 1-29 | SS-31 (Elamipretide) |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
SS-31 (Elamipretide)
- Elamipretide: First Approval.
Drugs, 2026
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Circulation. Heart failure, 2026
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
Neurochemical research, 2026
Ready to Learn More?
Looking for trusted sources?